ESR1 and breast carcinoma: In our joint modeling approach, CYP3A4/5 inhibitors were not associated with breast cancer recurrence; however, in our Cox modeling approach, CYP3A4/5 inhibitor use was associated with higher breast cancer recurrence risk in ER+ tamoxifen‐treated women vs. nonusers.